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Results

Introduction and Objectives
• Barriers exist within primary care that prevent
appropriate treatment for substance abuse disorder:
– Lack of institutional support for prescribing
buprenorphine due to insufficient staff training,
1
lack of time and complex regulations
– Lack of psychosocial and mental health support2
– Social stigma present within primary care
heavily represented though language, patient
identification and treatment3
• Goals:
– Develop a questionnaire that aims to identify
stigmatizing language towards individuals with
opioid use disorder across the interdisciplinary
teams to target training and education
– Conduct a pilot questionnaire to gather feedback
and improve the design to fully execute a larger
scale project with IRB approval in the near future

Method
Literature Review and
Community Observation

Questionnaire
Development

• Total of 12 articles found including 3
cohort studies and 2 meta analyses
• Attended 8 meetings with the PacMAT
team
• Developed three surveys including three
patients with moderate opioid use disorder
but varying socioeconomic backgrounds
and 9 follow up questions

Phase 1 Review

• Questionnaires developed and reviewed
with PacMAT Team

Phase 2 Review:
Pilot

• Questionnaire reviewed by the Stakeholder
Groups on the Task Force Team to collect
feedback on how to improve the
questionnaire

Conclusion

• 17 responses were recorded which provided feedback

Frequent Feedback Received
Remove at least one question
Replace 'suboxones' with 'buprenorphine’ in question 8
Question 8 should have the option to choose more than one answer
It is difficult to word a description of the patient and their urine test results to the
medical assistant as that is always done verbally and briefly
Figure 1 displays the most received feedback from participants during the pilot
Average time taken to complete the
questionnaire: 7 minutes

Original Questionnaire
“The patient took a urine drug screen and
the results indicated that she has recently
used fentanyl and marijuana. How would
you describe these drug test results to the
medical assistant?”
“What are your beliefs about this patient
and her response to the urine drug screen?
”
“It is decided to induce the patient on
suboxones and at her 60 day visit the
patient takes another urine test. The results
indicate that she has had a return to
substance use and there is no
buprenorphine metabolites in the urine, but
opioids are in the urine. What would your
approach be now for the patient?”
- Discontinue buprenorphine and refer to
higher level of care
- Mandate behavioral health care if
treatment will continue
-Ask patient about urine drug screen
results and recovery goals and move
forward from that place

Changes Made
“The patient took a urine drug screen and
the results indicated that she has recently
used fentanyl and marijuana. How would
you describe these drug test results to the
patient”
Question REMOVED

“It is decided to induce the patient on
buprenorphine and at her 60 day visit the
patient takes another urine test. The results
indicate that she has had a return to
substance use and there is no
buprenorphine metabolites in the urine, but
opioids are in the urine. What would your
approach be now for the patient? You may
choose more than one answer”
- Discontinue buprenorphine and refer to
higher level of care
- Mandate behavioral health care if
treatment will continue
-Ask patient about urine drug screen
results and recovery goals and move
forward from that place
-Other, please explain

Figure 2 displays the changes made to the questionnaire using the feedback

• Using the feedback from the 17 responses, changes
were made to the questionnaire to improve the design
• In total, 2 open ended questions were removed to
shorten the length of the survey
• Participants can now choose more than one answer in
the multiple choice question to ensure the participant
can fully express their desired treatment plan
• With changes made, it is estimated for the
questionnaire to now take an average of five minutes.
Each questionnaire now includes one patient case, 4
open ended questions, 1 multiple choice question, and
2 questions on a Likert scale

Future Directions
• Validate a stigma questionnaire and data tracking
system using the addictionary as a coding tool in order
to track stigmatizing language4
• Submission of an IRB in order to send the questionnaire
out on a greater scale
• Send questionnaire to each of the 14 primary care sites
• Collect an average stigma score at each of the 14
primary care practices
• Target the primary stigma at each practice and develop
changes in order to diminish the stigma against opioid
use disorder patients at each of the practices
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